Lilly to present new data across Zepbound, Foundayo, EloraTZP and retatrutide at ObesityWeek 2026, moving obesity care beyond the scale

Rhea-AI Summary

Eli Lilly and Company (LLY) reported obesity-treatment trial results ahead of presentations at ObesityWeek, taking place November 14–17, 2026.

Investigational EloraTZP, combining eloralintide and tirzepatide, produced up to an average 23.3% weight loss at 48 weeks in Phase 2 participants with obesity or overweight and type 2 diabetes. A1C, a measure of blood sugar, fell by up to an average 2.9%. Phase 3 retatrutide results showed reductions in sleep apnea severity and knee osteoarthritis pain. Zepbound reduced BMI by an average 21.4% at 72 weeks in adolescents with obesity. Eloralintide exit interviews also showed reported reductions in food cravings and food noise, meaning persistent thoughts about food.

12 points · 0 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 0 points

How the balance works

Positive

• Moderate pointPhase 2 EloraTZP produced up to an average 54.1 lbs (23.3%) weight loss at 48 weeks in adults with obesity or overweight and type 2 diabetes.
• Moderate pointEloraTZP lowered A1C by up to an average 2.9%, with up to 77% achieving normal blood sugar levels.
• Moderate pointTRIUMPH-1 retatrutide reduced sleep breathing disruptions by up to an average 36.1 events per hour (60.6%) at 80 weeks in adults with moderate-to-severe sleep apnea and obesity or overweight.
• Moderate pointTRIUMPH-2 retatrutide reduced sleep breathing disruptions by up to an average 28.4 events per hour (48.1%) at 80 weeks in adults with moderate-to-severe sleep apnea, obesity or overweight and type 2 diabetes.
• Moderate pointTRIUMPH-1 retatrutide reduced knee osteoarthritis pain scores by up to an average 4.3 points (73.1%) at 80 weeks in adults with obesity or overweight.
• Moderate pointTRIUMPH-4 retatrutide reduced knee osteoarthritis pain scores by up to an average 4.5 points (75.8%) at 68 weeks in adults with obesity or overweight.
• Moderate pointZepbound reduced BMI by an average 21.4% at 72 weeks in adolescents aged 12 to <18 years with obesity.

5 minor points

• Minor pointEloraTZP left up to 60% of Phase 2 participants no longer meeting BMI criteria for obesity.
• Minor pointZepbound left more than half of adolescent participants no longer meeting BMI criteria for obesity at 72 weeks.
• Minor pointZepbound-treated adolescents reported improved weight-related quality of life, including physical comfort and body esteem.
• Minor pointEloralintide exit interviews at 48 weeks showed 74% reporting fewer cravings and 52% reporting less food noise.
• Minor pointEloralintide exit interviews showed 41% of participants who drank alcohol at baseline reported drinking less at 48 weeks.

Negative

• None.

Key Figures

EloraTZP weight loss: up to an average of 54.1 lbs (23.3%) EloraTZP A1C reduction: up to an average of 2.9% EloraTZP no longer meeting BMI obesity criteria: up to 60% +5 more

EloraTZP weight loss

up to an average of 54.1 lbs (23.3%)

At 48 weeks; adults with obesity or overweight and type 2 diabetes

EloraTZP A1C reduction

up to an average of 2.9%

Phase 2 results in adults with obesity or overweight and type 2 diabetes

EloraTZP no longer meeting BMI obesity criteria

up to 60%

Phase 2 results

Retatrutide AHI reduction

up to an average of 36.1 events per hour (60.6%)

TRIUMPH-1; at 80 weeks in adults with moderate-to-severe OSA and obesity or overweight

Retatrutide AHI reduction

up to an average of 28.4 events per hour (48.1%)

TRIUMPH-2; at 80 weeks in adults with moderate-to-severe OSA, obesity or overweight, and type 2 diabetes

Retatrutide WOMAC pain reduction

up to an average of 4.3 points (73.1%)

TRIUMPH-1; at 80 weeks in adults with knee osteoarthritis pain and obesity or overweight

Retatrutide WOMAC pain reduction

up to an average of 4.5 points (75.8%)

TRIUMPH-4; at 68 weeks in adults with knee osteoarthritis pain and obesity or overweight

Zepbound BMI reduction

an average of 21.4%

At 72 weeks in adolescents aged 12 to <18 years with obesity

Historical Context

1 past event · Latest: Nov 09

1 event

1. Nov 09

   OSA data

   24h Move

   +4.3%

   Foundayo Phase 3 OSA results reported reduced breathing interruptions measured against placebo.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

a1c, apnea-hypopnea index, womac, glp-1, +1 more

5 terms

a1c medical

"EloraTZP also lowered A1C by up to an average of 2.9%"

A1C is a blood test that reports average blood sugar over about three months by measuring how much glucose sticks to hemoglobin, a protein in red blood cells. For investors, A1C acts like a long-term scorecard for diabetes treatments, devices and diagnostics: meaningful changes in A1C in clinical studies can affect regulatory approval, insurance coverage and commercial prospects, and thus influence a company's market value.

apnea-hypopnea index medical

"as measured by the apnea-hypopnea index (AHI)"

A measure of how often a person has pauses or shallow breaths during sleep, calculated as the average number of these events per hour. Investors care because this single number is used by doctors and insurers to diagnose sleep-disordered breathing and decide on treatments and device coverage, so higher or lower values can affect demand for diagnostic tools, therapies, and related healthcare spending—think of it as counting traffic jams per hour to judge road congestion.

womac medical

"as measured by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)"

A WOMAC is a standardized questionnaire patients complete to rate joint pain, stiffness, and ability to perform everyday activities, most often used for osteoarthritis. Think of it as a customer-satisfaction score for joints that translates how people actually feel and function into numbers. Investors watch WOMAC results because they are commonly used to show whether a treatment meaningfully helps patients, influencing regulatory approval, prescribing decisions and market value.

glp-1 medical

"dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1"

GLP-1 (glucagon-like peptide-1) is a natural hormone in the body that helps regulate blood sugar levels and appetite. Its significance to investors lies in its role as the basis for a class of medications that address conditions like type 2 diabetes and obesity, which are large and growing markets. Advances or investments in GLP-1-based treatments can signal opportunities in healthcare innovation and potentially impact pharmaceutical companies’ growth.

gip medical

"dual GIP (glucose-dependent insulinotropic polypeptide)"

GIP commonly stands for Global Infrastructure Partners, a private investment firm that buys and manages large physical assets such as airports, power plants, toll roads and pipelines. Investors pay attention because when GIP acquires, invests in, or sells such assets it can alter cash flow, debt levels and long-term plans for those businesses—like a new landlord changing rents or making upgrades—affecting revenue, dividends and risk for shareholders and creditors.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Phase 2 results showed EloraTZP, an investigational combination of eloralintide and tirzepatide, delivered substantial weight loss and A1C improvements in participants with obesity and type 2 diabetes

Results from TRIUMPH-1, TRIUMPH-2 and TRIUMPH-4 demonstrated retatrutide, an investigational triple agonist, reduced obstructive sleep apnea severity and knee osteoarthritis pain in adults with obesity

People reported Foundayo was simple and easy to use in a new real-world evidence study, while patient-reported outcomes showed that participants treated with eloralintide reported reductions in food noise, food cravings and alcohol consumption

INDIANAPOLIS, Nov. 14, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), will present new data across its cardiometabolic health portfolio at ObesityWeek 2026, taking place November 14 to 17, 2026, in Washington, D.C. The presentations span clinical trial results, patient-reported outcomes and real-world evidence and reflect Lilly's commitment to advancing potential treatment options that address health outcomes, day-to-day experiences and the diverse needs of people living with complex chronic diseases.

Kenneth Custer, Ph.D., Executive Vice President and President of Lilly Cardiometabolic Health: "Obesity care is about more than numbers on the scale: it is about improving overall health and addressing the myriad of ways the disease can affect daily life, through treatment options that meet different needs. At ObesityWeek 2026, new evidence across our portfolio reflects a broader view of care, including clinical outcomes for varied populations and obesity-related conditions, as well as the treatment experience for people who take these medicines. Together, these data reinforce how Lilly has helped to transform obesity care and continues to advance next-generation treatment options."

Select Lilly Presentations at ObesityWeek 2026

EloraTZP Phase 2 oral session | Sunday, November 15, 2026 | 3:30 to 4:30 p.m. ET
This oral session will present the latest Phase 2 data evaluating EloraTZP, an investigational combination of eloralintide and tirzepatide.

• Phase 2 results: EloraTZP delivered weight loss of up to an average of 54.1 lbs (23.3%) at 48 weeks from an average baseline of 232.4 lbs in adults with obesity or overweight and type 2 diabetes, with up to 60% no longer meeting the BMI criteria for obesity. EloraTZP also lowered A1C by up to an average of 2.9%, with up to 77% of participants achieving normal blood sugar levels.

Retatrutide and Zepbound (tirzepatide) oral session | Sunday, November 15, 2026 | 5:00 to 6:30 p.m. ET
This oral session will present Phase 3 results for both retatrutide, an investigational once-weekly GIP, GLP-1, and glucagon triple receptor agonist, and Zepbound.

• Retatrutide in Obstructive Sleep Apnea: In TRIUMPH-1, retatrutide reduced breathing disruptions during sleep, as measured by the apnea-hypopnea index (AHI), by up to an average of 36.1 events per hour (60.6%) at 80 weeks in adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity or overweight. In TRIUMPH-2, retatrutide reduced AHI by up to an average of 28.4 events per hour (48.1%) at 80 weeks in adults with moderate-to-severe OSA, obesity or overweight and type 2 diabetes.
• Retatrutide in Knee Osteoarthritis: In TRIUMPH-1, retatrutide reduced knee osteoarthritis pain, as measured by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale, by up to an average of 4.3 points (73.1%) at 80 weeks in adults with knee osteoarthritis pain and obesity or overweight. In TRIUMPH-4, retatrutide reduced WOMAC pain by up to an average of 4.5 points (75.8%) at 68 weeks in adults with knee osteoarthritis pain and obesity or overweight.
• SURMOUNT-ADOLESCENTS: Zepbound reduced BMI by an average of 21.4% in adolescents aged 12 to <18 years with obesity, with more than half no longer meeting the BMI criteria for obesity at 72 weeks. Participants also reported improvements in weight-related quality of life, including physical comfort and body esteem. 

Foundayo (orforglipron) Posters

• FOUNDERS real-world evidence Survey Results: In the survey, 96-98% of participants agreed the once-daily GLP-1 pill was simple, convenient and easy to use, regardless of when, how or with what they took it. Additionally, most participants took Foundayo with food, beverages or other oral medications, and about 40% took it in the evening, afternoon or bedtime.

Eloralintide Poster

• Eloralintide Phase 2 Participant Exit Interviews: At 48 weeks, participants treated with eloralintide reported reductions in food cravings and food noise, with 74% reporting fewer cravings, especially for sugary foods, and 52% reporting less food noise. Among those who drank alcohol at baseline, 41% reported drinking less.

About Zepbound (tirzepatide) injection
Zepbound (tirzepatide) is the first and only dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist obesity medication. Zepbound tackles an underlying cause of excess weight. It reduces appetite and how much you eat. Zepbound is indicated for adults with obesity, or some adults who are overweight and also have at least one weight-related medical problem, to lose weight and keep it off. Additionally, Zepbound is FDA-approved to treat adults with moderate-to-severe obstructive sleep apnea and obesity. Zepbound should be used with a reduced-calorie diet and increased physical activity.

About Foundayo (orforglipron)
Foundayo (orforglipron) is FDA-approved for adults with obesity, or some adults with overweight who also have weight-related medical problems, to reduce excess body weight and maintain weight reduction long term, alongside a reduced-calorie diet and increased physical activity. Foundayo is a once-daily small molecule (non-peptide) oral glucagon-like peptide-1 receptor agonist that can be taken any time of the day without restrictions on food and water intake. Orforglipron was discovered by Chugai Pharmaceutical Co., Ltd. and licensed by Lilly in 2018. In addition to chronic weight management, orforglipron is being studied as a potential treatment for type 2 diabetes, obstructive sleep apnea, osteoarthritis knee pain, hypertension, peripheral artery disease and stress urinary incontinence.

About retatrutide
Retatrutide is an investigational once-weekly triple hormone receptor agonist. Retatrutide is a single molecule that activates the body's receptors for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon. Lilly is studying retatrutide in several Phase 3 clinical trials to evaluate its potential efficacy and safety in obesity and overweight with at least one weight-related medical problem, type 2 diabetes, knee osteoarthritis, moderate-to-severe obstructive sleep apnea, chronic low back pain, cardiovascular and renal outcomes, and metabolic dysfunction-associated steatotic liver disease. Retatrutide is an investigational molecule that cannot be legally sold or marketed for human use.

About eloralintide
Eloralintide is an investigational once-weekly, selective amylin receptor agonist previously known as LY3841136. Eloralintide has the potential to decrease calorie intake, and the effects are likely mediated by affecting satiety, or the feeling of fullness. Phase 3 trials of eloralintide for the treatment of obesity and in adults with obesity or overweight with or without type 2 diabetes are currently ongoing. Lilly also conducted a Phase 2 study (NCT06603571) evaluating eloralintide, alone or in combination with tirzepatide, for weight management in adults with obesity or overweight and type 2 diabetes.

ZEPBOUND INDICATIONS AND SAFETY SUMMARY WITH WARNINGS

Zepbound^® (ZEHP-bownd) is an injectable prescription medicine used with a reduced-calorie diet and increased physical activity to help adults with:

• obesity, or some adults with overweight who also have weight-related medical problems, to lose excess body weight and keep the weight off.
• moderate-to-severe obstructive sleep apnea (OSA) and obesity to improve their OSA.
• Zepbound contains tirzepatide and should not be used with other tirzepatide-containing products or any GLP-1 receptor agonist medicines. It is not known if Zepbound is safe and effective for use in children.

Warnings - Zepbound may cause tumors in the thyroid, including thyroid cancer. Watch for possible symptoms, such as a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath. If you have any of these symptoms, tell your healthcare provider.

• Do not use Zepbound if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC).
• Do not use Zepbound if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• Do not use Zepbound if you have had a serious allergic reaction to tirzepatide or any of the ingredients in Zepbound.

KwikPen^®: Do not share your KwikPen with other people, even if the pen needle has been changed.  You may give other people a serious infection or get a serious infection from them.

Zepbound may cause serious side effects, including:

Severe stomach problems. Stomach problems, sometimes severe, have been reported in people who use Zepbound. Tell your healthcare provider if you have stomach problems that are severe or will not go away.

Dehydration leading to kidney problems. Diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems. It is important for you to drink fluids to help reduce your chance of dehydration. Tell your healthcare provider right away if you have nausea, vomiting, or diarrhea that does not go away.

Gallbladder problems. Gallbladder problems have happened in some people who use Zepbound. Tell your healthcare provider right away if you get symptoms of gallbladder problems, which may include pain in your upper stomach (abdomen), fever, yellowing of skin or eyes (jaundice), or clay-colored stools.

Inflammation of the pancreas (pancreatitis). Stop using Zepbound and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without nausea or vomiting. You may feel the pain from your abdomen to your back.

Serious allergic reactions. Stop using Zepbound and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue or throat, problems breathing or swallowing, severe rash or itching, fainting or feeling dizzy, or very rapid heartbeat.

Low blood sugar (hypoglycemia). Your risk for getting low blood sugar may be higher if you use Zepbound with medicines that can cause low blood sugar, such as a sulfonylurea or insulin. Signs and symptoms of low blood sugar may include dizziness or light-headedness, sweating, confusion or drowsiness, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability, mood changes, hunger, weakness or feeling jittery.

Changes in vision in patients with type 2 diabetes. Tell your healthcare provider if you have changes in vision during treatment with Zepbound.

Food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sleepiness (deep sedation). Zepbound may increase the chance of food getting into your lungs during surgery or other procedures. Tell all your healthcare providers that you are taking Zepbound before you are scheduled to have surgery or other procedures.

Common side effects
The most common side effects of Zepbound include nausea, diarrhea, vomiting, constipation, stomach (abdominal) pain, indigestion, injection site reactions, feeling tired, allergic reactions, belching, hair loss, and heartburn. These are not all the possible side effects of Zepbound. Talk to your healthcare provider about any side effect that bothers you or doesn't go away.

Tell your doctor if you have any side effects. You can report side effects at 1-800-FDA-1088 or www.fda.gov/medwatch.

Before using Zepbound

• Your healthcare provider should show you how to use Zepbound before you use it for the first time.
• Talk to your healthcare provider about low blood sugar and how to manage it. Tell your healthcare provider if you are taking medicines to treat diabetes including an insulin or sulfonylurea.
• If you take birth control pills by mouth, talk to your healthcare provider before you use Zepbound. Birth control pills may not work as well while using Zepbound. Your healthcare provider may recommend another type of birth control for 4 weeks after you start Zepbound and for 4 weeks after each increase in your dose of Zepbound.

Review these questions with your healthcare provider:

❑ Do you have other medical conditions, including problems with your pancreas, or severe problems with your stomach, such as slowed emptying of your stomach (gastroparesis) or problems digesting food?
❑ Do you take diabetes medicines, such as insulin or sulfonylureas?
❑ Do you have a history of diabetic retinopathy?
❑ Are you scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation)?
❑ Do you take any other prescription medicines or over-the-counter drugs, vitamins, or herbal supplements?
❑ Are you pregnant, plan to become pregnant, breastfeeding, or plan to breastfeed? Zepbound may harm your unborn baby. Tell your healthcare provider if you become pregnant while using Zepbound. Zepbound may pass into your breast milk. You should talk with your healthcare provider about the best way to feed your baby while using Zepbound.

• Pregnancy Exposure Registry: There is a pregnancy exposure registry for women who have taken Zepbound during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. Talk to your healthcare provider about how you can take part in this registry, or you may call 1-844-524-0039 or email at MILEregistry@thermofisher.com or visit https://pregnancyregistry.lilly.com/zepbound.

How to take

• Read the Instructions for Use that come with Zepbound.
• Use Zepbound exactly as your healthcare provider says.
• Use Zepbound with a reduced-calorie diet and increased physical activity.
• Inject Zepbound under the skin (subcutaneously) of your stomach (abdomen), thigh, or have another person inject in the back of the upper arm. Do not inject ZEPBOUND into a muscle (intramuscularly) or vein (intravenously).
• Use Zepbound 1 time each week, at any time of the day.
• Change (rotate) your injection site with each weekly injection. Do not use the same site for each injection.
• If you take too much Zepbound, call your healthcare provider, call the Poison Help line at 1-800-222-1222 or go to the nearest hospital emergency room right away.
• Zepbound is approved as a 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg injection.

Learn more
Zepbound is a prescription medicine. For more information, call 1-800-LillyRx (1-800-545-5979) or go to www.zepbound.lilly.com.

This summary provides basic information about Zepbound but does not include all information known about this medicine. Read the information that comes with your prescription each time your prescription is filled. This information does not take the place of talking with your healthcare provider. Be sure to talk to your healthcare provider about Zepbound and how to take it. Your healthcare provider is the best person to help you decide if Zepbound is right for you.

ZP CON BS 01SEP2026

Zepbound^®, its delivery device base and KwikPen^® are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.

FOUNDAYO INDICATION AND SAFETY SUMMARY WITH WARNINGS 
Foundayo (fown-DAY-oh) is a prescription medicine used with a reduced-calorie diet and increased physical activity to help adults with obesity, or some adults with overweight who also have weight-related medical problems, to lose excess body weight and keep the weight off. 

• Foundayo should not be used with other GLP-1 receptor agonist medicines. 
• It is not known if Foundayo is safe and effective for use in children. 

Warnings – Foundayo may cause tumors in the thyroid, including thyroid cancer. Watch for possible symptoms, such as a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath. If you have any of these symptoms, tell your healthcare provider. 

• Do not use Foundayo if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC). 
• Do not use Foundayo if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). 
• Do not use Foundayo if you have had a serious allergic reaction to orforglipron or any of the ingredients in Foundayo. 

Foundayo may cause serious side effects, including:
Inflammation of the pancreas (pancreatitis). Stop taking Foundayo and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without nausea or vomiting. Sometimes you may feel the pain from your abdomen to your back. 

Severe stomach problems. Stomach problems, sometimes severe, have been reported in people who use Foundayo. Tell your healthcare provider if you have stomach problems that are severe or will not go away. 

Dehydration leading to kidney problems. Diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems. It is important for you to drink fluids to help reduce your chance of dehydration. Tell your healthcare provider right away if you have nausea, vomiting, or diarrhea that does not go away. 

Low blood sugar (hypoglycemia). Your risk for getting low blood sugar may be higher if you use Foundayo with medicines that can cause low blood sugar, such as an insulin or sulfonylurea. Signs and symptoms of low blood sugar may include dizziness or light-headedness, sweating, confusion or drowsiness, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability, mood changes, hunger, weakness, or feeling jittery. 

Serious allergic reactions. Stop using Foundayo and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue or throat, problems breathing or swallowing, severe rash or itching, fainting or feeling dizzy, or very rapid heartbeat. 

Changes in vision in patients with type 2 diabetes. Tell your healthcare provider if you have changes in vision during treatment with Foundayo. 

Gallbladder problems. Gallbladder problems have happened in some people who use Foundayo. Tell your healthcare provider right away if you get symptoms of gallbladder problems, which may include pain in your upper stomach (abdomen), fever, yellowing of skin or eyes (jaundice), or clay-colored stools. 

Food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sleepiness (deep sedation). Foundayo may increase the chance of food getting into your lungs during surgery or other procedures. Tell your healthcare providers that you are taking Foundayo before you are scheduled to have surgery or other procedures. 

Common side effects 
The most common side effects of Foundayo include nausea, constipation, diarrhea, vomiting, indigestion, stomach (abdominal) pain, headache, swollen belly, feeling tired, belching, heartburn, gas, and hair loss. These are not all the possible side effects of Foundayo. Talk to your healthcare provider about any side effect that bothers you or doesn't go away. 

Tell your doctor if you have any side effects. You can report side effects at 1-800-FDA-1088 or www.fda.gov/medwatch. 

Before taking Foundayo 

• Tell your healthcare provider about all the medicines you take. Foundayo may affect the way some medicines work, and some medicines may affect the way Foundayo works. 
• Pregnancy Exposure Registry: There will be a pregnancy exposure registry for women who have taken Foundayo during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. Talk to your healthcare provider about how you can take part in this registry, or you may contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979). 
• If you take birth control pills by mouth, talk to your healthcare provider before you take Foundayo. Birth control pills may not work as well while taking Foundayo. Your healthcare provider may recommend another type of birth control for 30 days after starting Foundayo and for 30 days after each dose increase of Foundayo. 
• Talk to your healthcare provider about low blood sugar and how to manage it. Tell your healthcare provider if you are taking medicines to treat diabetes including an insulin or sulfonylurea. 

Review these questions with your healthcare provider:
❑ Do you have other medical conditions, including problems with your pancreas or kidneys, or severe problems with your liver, severe problems with your stomach, such as slowed emptying of your stomach (gastroparesis) or problems digesting food? 
❑ Do you have a history of diabetic retinopathy? 
❑ Are you scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation)? 
❑ Are you pregnant or plan to become pregnant? Foundayo may harm your unborn baby. 
❑ Are you breastfeeding or plan to breastfeed? Breastfeeding is not recommended during treatment with Foundayo. 
❑ Do you take any other prescriptions or over-the-counter medicines, vitamins, or herbal supplements? 

How to take 

• Take Foundayo exactly as your healthcare provider tells you to. 
• Use Foundayo with a reduced-calorie diet and increased physical activity. 
• Take Foundayo by mouth 1 time each day, with or without food. 
• Swallow tablets whole. Do not break, crush, or chew the tablet. 
• If you miss a dose, take it as soon as possible. Do not take 2 doses of Foundayo in the same day. 
• Do not take more than 1 tablet per day. 
• If you miss taking Foundayo for 7 or more days in a row, call your healthcare provider to talk about how to restart your treatment. 
• If you take too much Foundayo, call your healthcare provider or Poison Help line at 1-800-222-1222 or go to the nearest hospital emergency room right away. 

Learn more 
Foundayo is a prescription medicine available in 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, or 17.2 mg oral tablets. For more information, call 1-800-545-5979 or go to foundayo.lilly.com. 

This summary provides basic information about Foundayo but does not include all information known about this medicine. Read the information that comes with your prescription each time your prescription is filled. This information does not take the place of talking with your doctor. Be sure to talk to your doctor or other healthcare provider about Foundayo and how to take it. Your doctor is the best person to help you decide if Foundayo is right for you.

OG CON BS APR2026

About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. P-LLY

Trademarks and Trade Names
All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are referenced in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ^® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

Cautionary Statement Regarding Forward-Looking Statements  
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995), including about Zepbound (tirzepatide), Foundayo (orforglipron), retatrutide, eloralintide, and EloraTZP as potential treatments for adults with obesity and/or type 2 diabetes and the timeline for future readouts, presentations, and other milestones relating to Foundayo, retatrutide, eloralintide and EloraTZP and its clinical trials, and reflects Lilly's current beliefs and expectations. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of drug research, development, and commercialization. Among other things, there is no guarantee that planned or ongoing studies will be completed as planned, that future study results will be consistent with study results to date, that product candidates will prove to be safe and effective treatments for relevant indications or receive regulatory approval or additional regulatory approvals, or that Lilly will execute its strategy as expected. For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.

Refer to:	Meghan Hindman; meghan.hindman@lilly.com (Media)
	Michael Czapar; czapar_michael_c@lilly.com (Investors)

 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/lilly-to-present-new-data-across-zepbound-foundayo-eloratzp-and-retatrutide-at-obesityweek-2026-moving-obesity-care-beyond-the-scale-302938569.html

SOURCE Eli Lilly and Company

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Lilly's EloraTZP Phase 2 obesity trial show?

EloraTZP produced up to an average 54.1 lbs (23.3%) weight loss at 48 weeks from an average baseline of 232.4 lbs in adults with obesity or overweight and type 2 diabetes. The investigational combination of eloralintide and tirzepatide also lowered A1C by up to an average 2.9%.

What did Lilly's Zepbound adolescent obesity trial show?

In SURMOUNT-ADOLESCENTS, Zepbound reduced BMI by an average 21.4% at 72 weeks in adolescents aged 12 to <18 years with obesity. More than half no longer met BMI criteria for obesity, and participants reported improvements in weight-related quality of life.